InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,488.00
(
-0.25%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
0.00%
)
Bitcoin
69,192.37
(
-0.17%
)
Post# of 316685
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cintrix

Send PM Follow Ignore
Followers 364
Posts 113858
Boards Moderated 5
Alias Born 12/28/2000

cintrix

Member Level

Re: None

Thursday, 03/21/2024 9:39:29 AM

Thursday, March 21, 2024 9:39:29 AM

Post# of 316685
TRML down 35% Tourmaline (NASDAQ: TRML) shares are trading lower after Roche (OTC: RHHBY) partner, Chugai Pharmaceutical Co., reported disappointing clinical benefit results of Enspryng, an interleukin-6 (IL-6) inhibitor, as an investigational treatment for generalized myasthenia gravis (gMG). Tourmaline is currently developing TOUR006, which also targets interleukin-6 (IL-6). Argenx (NASDAQ: ARGX) is trading higher off the Chugai and Roche data.
https://www.biopharmcatalyst.com/news/2024/tourmaline-trml-argenx-argx-off-rhhby-data-theratechnologies-thtx-part-3-dosing
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up